ArticleThe lancet. HIV2022

Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.

Theodore D Ruel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.